Crestor, Zocor Comparison May Be More Useful Than ASTEROID – Editorial

A trial comparing high doses of AstraZeneca's Crestor and Merck's Zocor would be more informative than the open label, single-arm ASTEROID study evaluating the effects of high-intensity Crestor on regression of coronary atherosclerosis, according to an editorial in the March 13 issue of the Journal of the American Medical Association

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet